Merck & Co., Inc. (BMV:MRK)
Mexico · Delayed Price · Currency is MXN | Market Cap | 4.97T +26.9% |
| Revenue (ttm) | 1.19T +2.9% |
| Net Income | 161.08B -48.8% |
| EPS | 64.46 -48.0% |
| Shares Out | n/a |
| PE Ratio | 30.84 |
| Forward PE | 18.69 |
| Dividend | 60.88 (3.06%) |
| Ex-Dividend Date | Mar 16, 2026 |
| Volume | n/a |
| Average Volume | 1,766 |
| Open | 2,103.00 |
| Previous Close | 1,995.00 |
| Day's Range | 2,103.00 - 2,103.00 |
| 52-Week Range | 1,430.01 - 2,182.00 |
| Beta | 0.20 |
| RSI | 51.63 |
| Earnings Date | Aug 4, 2026 |
About Merck & Co.
Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock produ... [Read more]
Financial Performance
In 2025, Merck & Co.'s revenue was $65.01 billion, an increase of 1.31% compared to the previous year's $64.17 billion. Earnings were $18.25 billion, an increase of 6.64%.
Financial numbers in USD Financial StatementsNews
Merck Stock Climbs on Cancer Data. Why the Drugmaker Is More Than a One-Trick Pony.
Merck shares rose after partner Kelun-Biotech reported positive late-stage trial results for a Keytruda combination treatment in lung cancer.
Merck receives positive CHMP opinion for KEYTRUDA plus Padcev
Merck (MRK) announced the European Medicines Agency’s Committee for Medicinal Products for Human Use adopted a positive opinion recommending approval of KEYTRUDA, Merck’s anti-PD-1 therapy, in combina...
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as Perioperative Treatment for Adults With Cisplatin-Ineligible Resectable Muscle-Invasive Bladder Cancer
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the European Medicines Agency's Committee for Medicinal Products for Human Use (...
Kelun, Merck's lung cancer combo improves survival in late-stage China trial
Sichuan Kelun-Biotech Biopharmaceutical said on Thursday its experimental treatment combined with partner Merck's Keytruda improved survival rate in patients with advanced lung cancer, meeting the ma...
Moderna, Merck cancer combo cuts melanoma spread risk at five years
Moderna and Merck's combination therapy for skin cancer helped reduce risk of cancer spreading to another part of the body by 59% after five years of follow-up, data from a mid-stage trial showed Th...
Merck Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer
DARMSTADT, Germany--(BUSINESS WIRE)--Merck Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer.
National Advertising Review Board Refers Merck Animal Health to FTC and FDA for Bravecto Quantum Dosing Claims
A panel of the National Advertising Review Board (NARB), the appellate advertising body of BBB National Programs, has referred Intervet, Inc. (d/b/a Merck Animal Health) to the Federal Trade Commissio...
Exelixis announces clinical development collaboration with Merck
Exelixis (EXEL) announced that the company has entered into a clinical development collaboration with Merck (MRK), known as MSD outside of the United States and Canada, to supply Keytrude Qlex…
Merck’s Sac-TMT met primary endpoints in endometrial cancer trial
Merck (MRK) announced the pivotal Phase 3 TroFuse-005 trial evaluating sacituzumab tirumotecan, or sac-TMT, an investigational TROP2-directed antibody-drug conjugate, or ADC, being developed in collab...
Merck's endometrial cancer drug meets late-stage trial goals
Merck said on Monday its experimental endometrial cancer drug met the main goals of a late-stage trial.
Merck Announces TroFuse-005 Trial Evaluating Sacituzumab Tirumotecan (Sac-TMT) Met Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck's TroFuse-005 Trial Evaluating Sac-TMT Met Primary Endpoints of OS and PFS in Certain Patients With Advanced or Recurrent Endometrial Cancer.
Merck Highlights New Long-Term Data and Advancements Across Broad Oncology Portfolio and Pipeline Research at ASCO 2026
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced new research from more than 100 abstracts across over 25 types of ...
Erasca enters AURORAS-1 clinical trial pact, supply agreement with Merck
Erasca (ERAS) announced a clinical trial collaboration and supply agreement with Merck (MRK). This agreement supports a clinical proof-of-concept study, AURORAS-1, evaluating the pan-RAS molecular glu...
Merck Scientists Publish Landmark Paper on Novel Method for Large-Scale Biocatalytic Synthesis of Investigational Oral PCSK9 Inhibitor, Enlicitide Decanoate
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today the publication of work describing the large-scale synthesis of enlicitide decanoat...
Merck reinstated with a Neutral at Citi
Citi analyst Geoff Meacham reinstated coverage of Merck (MRK) with a Neutral rating and $125 price target Citi views the company’s Q1 report as solid but wants to see positive…
Merck Animal Health Selects Salesforce's Agentforce Life Sciences for Customer Engagement to Transform Animal Care and Enhance Support Experiences for Employees
SAN FRANCISCO & RAHWAY, N.J.--(BUSINESS WIRE)--Salesforce (NYSE: CRM), the world's #1 AI CRM, and Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of...
Merck Completes Acquisition of Terns Pharmaceuticals, Inc.
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the successful completion of the acquisition of Terns Pharmaceuticals, Inc. (“Te...
Merck (MRK) Price Forecast: Double Top Signals Deeper Correction Risk
Merck stock shows a confirmed double top breakdown, signaling potential downside risk, while key moving averages and resistance zones now shape the outlook for a deeper correction.
Merck & Co. Earnings Call Transcript: Q1 2026
Q1 revenue grew 5% year-over-year to $16.3B, led by oncology and animal health, but a $9B one-time charge for Sedera resulted in a reported loss. Guidance for 2026 was raised, with continued investment in launches and pipeline, and the Terns acquisition expected to further diversify growth.
Merck & Co. Earnings release: Q1 2026
Merck & Co. released its Q1 2026 earnings on April 30, 2026, summarizing the period's financial results.
Merck & Co. Slides: Q1 2026
Merck & Co. has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on April 30, 2026.
Merck & Co. Quarterly report: Q1 2026
Merck & Co. has published its Q1 2026 quarterly earnings report on April 30, 2026.
Merck Announces First Dose in Phase 3 Study with Enpatoran for Lupus Patients with Active Skin Manifestations
DARMSTADT, Germany--(BUSINESS WIRE)--Merck, a leading global science and technology company, today announced the first patient was dosed in the Phase 3 program, ELOWEN-1 (NCT07332481) and ELOWEN-2 (NC...
Merck Sales Rise on Continued Keytruda Growth
Merck reported higher first-quarter sales and raised its full-year earnings guidance as demand for its flagship Keytruda cancer drug continues to grow.
Merck beats quarterly estimates on strength of Keytruda and new products, narrows outlook
Merck reported first-quarter results that topped estimates on strong demand for its cancer immunotherapy Keytruda and some newer products. The pharmaceutical giant also narrowed its 2026 sales guidan...